Abstract
The Food and Drug Administration has approved three drugs from a new drug class designed to prevent migraine headaches. The drugs target calcitonin gene–related peptide, a substance involved in the excessive cerebral vasodilation that leads to migraine headaches.The three new products are administered subcutaneously once per month.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call